Rising Prevalence Of Blood Clots Fuels Growth In The Pulmonary Embolism Market: The Driving Engine Behind Pulmonary Embolism Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Pulmonary Embolism Market Size Growth Forecast: What to Expect by 2025?
The market addressing pulmonary embolism has experienced swift expansion recently, projected to increase its valuation from $2.03 billion in 2024 to $2.26 billion the following year, reflecting an 11.4% compound annual growth rate. This historical upward trajectory is largely propelled by developments in anticoagulant treatments, ongoing clinical study efforts, heightened public and medical awareness concerning pulmonary embolism, and robust VTE prophylaxis measures.

How Will the Pulmonary Embolism Market Size Evolve and Grow by 2029?
Anticipation is high for significant expansion within the pulmonary embolism market over the forthcoming period, projecting its valuation to reach $3.62 billion by 2029, driven by a compound annual growth rate (CAGR) of 12.5%; this upward trajectory is fueled by advancements such as focused therapeutic approaches, the utilization of telemedicine alongside remote surveillance capabilities, efforts aimed at achieving health equity, and wider global health programs, while key developments shaping the market landscape include the integration of artificial intelligence for diagnostic purposes, the introduction of new anticoagulant medications, the establishment of specialized pulmonary embolism response teams, and a stronger emphasis on care tailored to individual patient needs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

What Drivers Are Propelling the Growth of Pulmonary Embolism Market Forward?
Anticipated escalation in the occurrence of blood clots is set to boost the expansion of the pulmonary embolism market moving ahead. A thrombus, which is the technical term for a blood clot, constitutes a gelatinous or semi-solid accumulation developing inside a blood vessel. Such obstructions significantly heighten the danger of pulmonary embolism because they impede circulation to the pulmonary system; these blockages often originate in the deep veins of the lower extremities, thereby elevating the probability of a pulmonary embolism event. To illustrate this impact, Gavi, the Vaccine Alliance-an international body established to enhance availability of novel and less commonly utilized immunizations for children-reported in an April 2022 publication that within the first month after COVID-19 exposure, researchers observed a thirty-threefold surge in the likelihood of life-threatening clots lodging in the lungs, alongside a fivefold greater risk of deep vein thrombosis. Consequently, the rising incidence of these blood clots is the key factor propelling the pulmonary embolism market's development.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

Which Emerging Trends Are Transforming the Pulmonary Embolism Market in 2025?
Leading firms within the pulmonary embolism sector are concentrating their efforts on creating cutting-edge medical tools, such as the Triever16 Curve catheter and the RevCore thrombectomy catheter, as a means to secure superior market positioning. Specifically, the US medical device firm Inari Medical Inc. introduced both the Triever16 Curve catheter and the RevCore thrombectomy catheter in June 2023. This newly released Triever16 Curve catheter has been engineered for use in pulmonary embolism interventions and peripheral thrombectomy operations; its design boasts excellent trackability and a purposefully shaped curve facilitating precise aspiration, further offering a specialized structure enabling seamless connection to larger, more powerful 20F or 24F catheters; concurrently, the RevCore thrombectomy catheter addresses venous in-stent thrombosis via its function as a mechanical thrombectomy instrument that employs a basket made of nitinol to trap and extract emboli, and ultimately, the implementation of these catheters is shown to enhance both the security and efficacy of treatments for pulmonary embolism.

What Are the Key Segments in the Pulmonary Embolism Market?
The pulmonary embolismmarket covered in this report is segmented -

1) By Treatment: Medications; Mechanical Devices; Other Treatments
2) By Diagnosis: Chest X-Ray; Electrocardiogram (ECG); Magnetic Resonance Imaging (MRI); Computed Tomography Scan; Pulmonary Angiography; Venography; Venous Ultrasound; D-Dimer Test; Other Diagnosis
3) By Symptoms: Shortness Of Breath; Chest Pain; Cough; Irregular Heartbeat; Dizziness; Fever; Cyanosis; Other Symptoms
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:
1) By Medications: Anticoagulants; Thrombolytics
2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters; Catheter-Assisted Thrombectomy
3) By Other Treatments: Surgical Embolectomy; Supportive Care

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

Who Are the Key Players Shaping the Pulmonary Embolism Market's Competitive Landscape?
Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

What Geographic Markets Are Powering Growth in the Pulmonary Embolism Market?
North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.